Posted Oct. 31, 2012 at 6:53 a.m.

Premium Lock RTP-based BioCryst withdraws hepatitis C drug application

Published: 2012-10-31 06:53:17
Updated: 2012-10-31 06:53:17

BioCryst BioCryst

BioCryst Pharmaceuticals says it is withdrawing its investigational new drug application for a proposed treatment of hepatitis C due to safety concerns....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll